Tesaro Inc. (TSRO) Sets New 52-Week High at $99.28
Tesaro Inc. (NASDAQ:TSRO) shares reached a new 52-week high during trading on Monday . The stock traded as high as $99.28 and last traded at $98.64, with a volume of 1,074,303 shares trading hands. The stock had previously closed at $95.03.
Several research firms recently commented on TSRO. RBC Capital Markets began coverage on Tesaro in a research note on Friday, August 12th. They issued an “outperform” rating and a $122.00 price objective for the company. Royal Bank Of Canada began coverage on Tesaro in a research note on Friday, August 12th. They issued an “outperform” rating and a $122.00 price objective for the company. Citigroup Inc. increased their price objective on Tesaro from $90.00 to $120.00 and gave the company a “buy” rating in a research note on Monday, August 8th. Credit Suisse Group AG restated a “buy” rating on shares of Tesaro in a report on Friday, August 5th. Finally, Jefferies Group set a $80.00 target price on Tesaro and gave the company a “hold” rating in a report on Friday, August 5th. Two equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $85.50.
The stock has a 50-day moving average of $91.96 and a 200-day moving average of $56.36. The stock’s market cap is $4.76 billion.
Tesaro (NASDAQ:TSRO) last issued its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported ($1.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.71) by $0.43. During the same period in the prior year, the firm posted ($1.51) earnings per share. The firm had revenue of $36.60 million for the quarter, compared to analyst estimates of $4.98 million. On average, equities research analysts forecast that Tesaro Inc. will post ($7.31) earnings per share for the current year.
In related news, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the transaction, the vice president now directly owns 12,500 shares of the company’s stock, valued at $929,375. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction on Friday, June 10th. The stock was sold at an average price of $40.75, for a total value of $285,250.00. Following the transaction, the vice president now directly owns 3,500 shares of the company’s stock, valued at $142,625. The disclosure for this sale can be found here.
A number of institutional investors have recently modified their holdings of the company. Rhumbline Advisers boosted its position in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock valued at $1,172,000 after buying an additional 1,915 shares in the last quarter. Bank of Montreal Can boosted its position in shares of Tesaro by 9,925.5% in the fourth quarter. Bank of Montreal Can now owns 24,362 shares of the biopharmaceutical company’s stock valued at $1,275,000 after buying an additional 24,119 shares in the last quarter. Finally, Jennison Associates LLC boosted its position in shares of Tesaro by 157.5% in the fourth quarter. Jennison Associates LLC now owns 938,461 shares of the biopharmaceutical company’s stock valued at $49,100,000 after buying an additional 574,041 shares in the last quarter.
TESARO, Inc is an oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. It operates in business of developing and commercializing oncology-focused therapeutics segment. It has in-licensed and are developing oncology-related product candidates, including intravenous (IV) rolapitant and niraparib, as well as product candidates under its immuno-oncology platform.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.